Zacks Investment Research on MSN

Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $381.87, demonstrating a +1.39% change from the preceding day's closing price. The stock outpaced the S&P 500's daily loss of 0.5%. At ...

Vertex Pharmaceuticals: Trikafta And Alyftrek Cement Market Leadership

Vertex's revenue was $2.96 billion in the second quarter of 2025, beating the consensus forecast by $58 million. Click here ...

A new way to see the hidden complexity of our genes

Scientists from James Cook University have developed a new computer tool that reveals layers of gene activity that were ...
Rock Paper Shotgun

Civilization 7 dev explains how the revamped 4X map generator bolts together continents from Voronoi diagrams

Firaxis and 2K continue to twiddle with Civilization 7's exploration phase, adding new map generators that produce more ...
Zacks Investment Research on MSN

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

FDA Grants Vertex Kidney Disease Drug Breakthrough Therapy Designation

The FDA granted breakthrough therapy designation to a Vertex Pharmaceuticals kidney disease drug.